Medicine Creek Analytics

Participants offered feedback to DOH staff questions related to their medical cannabis testing requirements and then posed questions of their own to officials.

Efforts to draft improved cannabis testing and additive rules drew skepticism and questions from attendees worried about testing standards, synthetic cannabinoids, enforcement, and more.

Staff went over a reorganization at WSDA including hemp and cannabis programs; the transition of lab standards and accreditation authority; plus tips for hemp licensees.

Officials outlined a transition period to take on accreditation authority in parallel with revising standards, including method approval and when enforcement of new standards would start.

Attendees had many suggestions and questions for WSLCB staff regarding draft rules for medically endorsed retailers, with emphasis around expected levels of enforcement.

DOH staff heard stories and suggestions from patients, advocates, and other stakeholders on how to improve affordability, access, and understanding of medically compliant cannabis products.

Staff heard from a few attendees with lab experience about potential changes in rule from SB 5367, focusing on definitions for THC content and synthesized cannabinoids.

Updates on two subgroups included a rehashing of why some technologies and testing regimes had been favored by a prior task force as staff looked ahead to finalizing recommendations.

A mostly new team at the DOH Medical Cannabis Program solicited feedback on potential revisions to rules on compliant products, testing, labeling, and logos.

With DOE staff moving forward on cannabis lab accreditation rulemaking, they explained the expected timeline for draft rules and heard feedback about the costly implications for labs.